Literature DB >> 24297069

Ocular delivery of pRNA nanoparticles: distribution and clearance after subconjunctival injection.

Liang Feng1, S Kevin Li, Hongshan Liu, Chia-Yang Liu, Kathleen LaSance, Farzin Haque, Dan Shu, Peixuan Guo.   

Abstract

PURPOSE: RNA nanoparticles derived from the three-way junction (3WJ) of the pRNA of bacteriophage phi29 DNA packaging motor were previously found to be thermodynamically stable. As the nanoparticles could have potential in ocular drug delivery, the objectives in the present study were to investigate the distribution of pRNA nanoparticles after subconjunctival injection and examine the feasibility to deliver the nanoparticles to the cells of cornea and retina.
METHODS: Alexa647-labeled pRNA nanoparticles (pRNA-3WJ and pRNA-X) and double-stranded RNA (dsRNA) were administered via subconjunctival injection in mice. Alexa647 dye was a control. Topical administration was performed for comparison. Ocular clearance of pRNA nanoparticles and dsRNA after the injection was assessed using whole-body fluorescence imaging of the eyes. The numbers of cells in the ocular tissues with nanoparticle cell internalization were determined in fluorescence microscopy of dissected eye tissues.
RESULTS: After subconjunctival injection, pRNA nanoparticles and dsRNA were observed to distribute into the eyes and cleared through the lymph. pRNA-3WJ, pRNA-X, and dsRNA were found in the cells of the conjunctiva, cornea, and sclera, but only pRNA-X was in the cells of the retina. Topical administration was not effective in delivering the nanoparticles to the eye.
CONCLUSIONS: The pRNA nanoparticles were delivered to the cells in the eye via subconjunctival injection, and cell internalization was achieved in the cornea with pRNA-3WJ and pRNA-X and in the retina with pRNA-X. Only the X-shape pRNA-X could enter the retina.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24297069      PMCID: PMC4124000          DOI: 10.1007/s11095-013-1226-x

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  45 in total

1.  Corneal penetration of topical and subconjunctival bevacizumab.

Authors:  Mohammad H Dastjerdi; Zahra Sadrai; Daniel R Saban; Qiang Zhang; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-07       Impact factor: 4.799

2.  Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration.

Authors:  Aniruddha C Amrite; Uday B Kompella
Journal:  J Pharm Pharmacol       Date:  2005-12       Impact factor: 3.765

3.  Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Stephanie H Kim; Craig J Galbán; Robert J Lutz; Robert L Dedrick; Karl G Csaky; Martin J Lizak; Nam Sun Wang; Ginger Tansey; Michael R Robinson
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-02       Impact factor: 4.799

Review 4.  Strategies for silencing human disease using RNA interference.

Authors:  Daniel H Kim; John J Rossi
Journal:  Nat Rev Genet       Date:  2007-03       Impact factor: 53.242

Review 5.  Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology.

Authors:  Peixuan Guo; Farzin Haque; Brent Hallahan; Randall Reif; Hui Li
Journal:  Nucleic Acid Ther       Date:  2012-08       Impact factor: 5.486

Review 6.  Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.

Authors:  Elias Fattal; Amélie Bochot
Journal:  Adv Drug Deliv Rev       Date:  2006-09-15       Impact factor: 15.470

7.  Characterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab.

Authors:  He Wen; Jinsong Hao; S Kevin Li
Journal:  J Pharm Sci       Date:  2012-12-04       Impact factor: 3.534

Review 8.  Delivery and biodistribution of siRNA for cancer therapy: challenges and future prospects.

Authors:  Shaguna Seth; Rachel Johns; Michael V Templin
Journal:  Ther Deliv       Date:  2012-02

9.  Single-stranded oligonucleotide-mediated in vivo gene repair in the rd1 retina.

Authors:  Charlotte Andrieu-Soler; Mounia Halhal; Jeffrey H Boatright; Staci A Padove; John M Nickerson; Eva Stodulkova; Rachael E Stewart; Vincent T Ciavatta; Marc Doat; Jean-Claude Jeanny; Therèse de Bizemont; Florian Sennlaub; Yves Courtois; Francine Behar-Cohen
Journal:  Mol Vis       Date:  2007-05-02       Impact factor: 2.367

Review 10.  Interfering with disease: a progress report on siRNA-based therapeutics.

Authors:  Antonin de Fougerolles; Hans-Peter Vornlocher; John Maraganore; Judy Lieberman
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

View more
  20 in total

1.  The Use of Minimal RNA Toeholds to Trigger the Activation of Multiple Functionalities.

Authors:  Kirill A Afonin; Mathias Viard; Philip Tedbury; Eckart Bindewald; Lorena Parlea; Marshall Howington; Melissa Valdman; Alizah Johns-Boehme; Cara Brainerd; Eric O Freed; Bruce A Shapiro
Journal:  Nano Lett       Date:  2016-02-29       Impact factor: 11.189

2.  RNA nanoparticle distribution and clearance in the eye after subconjunctival injection with and without thermosensitive hydrogels.

Authors:  Zhanquan Shi; S Kevin Li; Ponwanit Charoenputtakun; Chia-Yang Liu; Daniel Jasinski; Peixuan Guo
Journal:  J Control Release       Date:  2017-11-21       Impact factor: 9.776

Review 3.  Non-viral therapeutic approaches to ocular diseases: An overview and future directions.

Authors:  Rahel Zulliger; Shannon M Conley; Muna I Naash
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

4.  Programmable Nucleic Acid Based Polygons with Controlled Neuroimmunomodulatory Properties for Predictive QSAR Modeling.

Authors:  Morgan Brittany Johnson; Justin R Halman; Emily Satterwhite; Alexey V Zakharov; My N Bui; Kheiria Benkato; Victoria Goldsworthy; Taejin Kim; Enping Hong; Marina A Dobrovolskaia; Emil F Khisamutdinov; Ian Marriott; Kirill A Afonin
Journal:  Small       Date:  2017-09-18       Impact factor: 13.281

5.  Opportunities, Barriers, and a Strategy for Overcoming Translational Challenges to Therapeutic Nucleic Acid Nanotechnology.

Authors:  Kirill A Afonin; Marina A Dobrovolskaia; George Church; Mark Bathe
Journal:  ACS Nano       Date:  2020-07-24       Impact factor: 15.881

Review 6.  Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases.

Authors:  I Bravo-Osuna; V Andrés-Guerrero; P Pastoriza Abal; I T Molina-Martínez; R Herrero-Vanrell
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

7.  Topical Delivery of Senicapoc Nanoliposomal Formulation for Ocular Surface Treatments.

Authors:  Jie Liang Phua; Aihua Hou; Yuan Siang Lui; Tanima Bose; George Kanianthara Chandy; Louis Tong; Subbu Venkatraman; Yingying Huang
Journal:  Int J Mol Sci       Date:  2018-09-29       Impact factor: 5.923

Review 8.  Recent perspectives on the delivery of biologics to back of the eye.

Authors:  Mary Joseph; Hoang M Trinh; Kishore Cholkar; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Deliv       Date:  2016-09-06       Impact factor: 6.648

Review 9.  Cellular Delivery of RNA Nanoparticles.

Authors:  Lorena Parlea; Anu Puri; Wojciech Kasprzak; Eckart Bindewald; Paul Zakrevsky; Emily Satterwhite; Kenya Joseph; Kirill A Afonin; Bruce A Shapiro
Journal:  ACS Comb Sci       Date:  2016-08-26       Impact factor: 3.784

Review 10.  RNA versatility, flexibility, and thermostability for practice in RNA nanotechnology and biomedical applications.

Authors:  Farzin Haque; Fengmei Pi; Zhengyi Zhao; Shanqing Gu; Haibo Hu; Hang Yu; Peixuan Guo
Journal:  Wiley Interdiscip Rev RNA       Date:  2017-11-03       Impact factor: 9.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.